Article Information
History
- April 26, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Subhash Thuluva1,*,
- Vikram Paradkar1,
- SubbaReddy Gunneri1,
- Vijay Yerroju1,
- Rammohan Mogulla1,
- Pothakamuri Venkata Suneetha1,
- Kishore Turaga1,
- Mahesh Kyasani1,
- Senthil Kumar Manoharan1,
- Srikanth Adabala1,
- Aditya Sri Javvadi1,
- Guruprasad Medigeshi2,
- Janmejay Singh2,
- Heena Shaman2,
- Akshay Binayke2,
- Aymaan Zaheer2,
- Amit Awasthi2,
- Manish Narang3,
- Pradeep Nanjappa4,
- Niranjana Mahantshetti5,
- Bishan Swarup Garg6 and
- Mandal Ravindra Nath Ravi7
- 1Biological E Limited, 18/1&3, Azamabad, Hyderabad – 500 020, Telangana, India
- 2Vaccine and Infectious Disease Research Center, Translational Health Science and Technology Institute, Faridabad 121001, India
- 3Guru Teg Bahadur Hospital (GTB), Delhi, India
- 4Cheluvamba Hospital, Mysore, Karnataka, India
- 5KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Belagavi, Karnataka, India
- 6Mahatma Gandhi Institute of Medical Sciences (MGIMS), Wardha, Maharashtra, India
- 7ESIC Medical College & Hospital, Faridabad, Haryana, India
- ↵*Corresponding Author Name:
Subhash Thuluva, Biological E Limited, 18/1&3, Azamabad, Hyderabad – 500 020, Telangana, India, Phone:
+91 40 7121 6248. E-mail:
subhash.thuluva{at}biologicale.com
Authors’ Contribution: ST and VP conceptualized the study and edited the manuscript for intellectual content. ST, SG, VY, RM, PVS and KT curated, accessed and verified the data and helped in interim report generation. VP, MK, SKM, SA, ASJ, GM, JS and HS led the immunogenicity experiments. GM, JS and HS also contributed in performing and analyzing the neutralizing antibody assays. AB, AZ and AA contributed in performing the ELISpot testing for cellular immune response assessment. MS, PN, NM, BSG and MRNR were the key contributors of study conduct. ST was responsible for overall supervision of the project. All authors contributed to data interpretation, reviewing, and editing this manuscript.
Posted April 26, 2022.
Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study
